Olverembatinib demonstrated activity in patients with CP-CML who received first- or second-generation TKIs as first-line therapy.

Karnataka: Shilpa Medicare has received the Good Manufacturing Practice (GMP) Certification after the successful closure of ...

The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of ...

Frontline tyrosine kinase inhibitors are well-established for chronic myelogenous leukemia, but some patients experience inadequate response or adverse events, highlighting the need for novel ...